EP0950060A4 - Gegenstrang-hemmung von menschlichen adhäsionsmolekülen - Google Patents

Gegenstrang-hemmung von menschlichen adhäsionsmolekülen

Info

Publication number
EP0950060A4
EP0950060A4 EP96945380A EP96945380A EP0950060A4 EP 0950060 A4 EP0950060 A4 EP 0950060A4 EP 96945380 A EP96945380 A EP 96945380A EP 96945380 A EP96945380 A EP 96945380A EP 0950060 A4 EP0950060 A4 EP 0950060A4
Authority
EP
European Patent Office
Prior art keywords
adhesion molecules
antisense inhibition
human adhesion
human
antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP96945380A
Other languages
English (en)
French (fr)
Other versions
EP0950060A1 (de
Inventor
Glenn D Hoke
Matthews O Bradley
Taffy J Williams
Che-Hung Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dyad Pharmaceutical Corp
Original Assignee
Dyad Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyad Pharmaceutical Corp filed Critical Dyad Pharmaceutical Corp
Publication of EP0950060A1 publication Critical patent/EP0950060A1/de
Publication of EP0950060A4 publication Critical patent/EP0950060A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
EP96945380A 1996-12-02 1996-12-02 Gegenstrang-hemmung von menschlichen adhäsionsmolekülen Withdrawn EP0950060A4 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1996/019194 WO1998024797A1 (en) 1996-12-02 1996-12-02 Antisense inhibition of human adhesion molecules

Publications (2)

Publication Number Publication Date
EP0950060A1 EP0950060A1 (de) 1999-10-20
EP0950060A4 true EP0950060A4 (de) 2000-07-05

Family

ID=22256225

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96945380A Withdrawn EP0950060A4 (de) 1996-12-02 1996-12-02 Gegenstrang-hemmung von menschlichen adhäsionsmolekülen

Country Status (5)

Country Link
EP (1) EP0950060A4 (de)
JP (1) JP2001505432A (de)
AU (1) AU1564897A (de)
CA (1) CA2273203A1 (de)
WO (1) WO1998024797A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19844111A1 (de) * 1998-09-25 2000-04-20 Deutsches Krebsforsch Antisense-Sequenzen für die Hemmung der Expression des Adhäsionsmoleküls ICAM-1
WO2000018907A2 (de) * 1998-09-25 2000-04-06 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Antisense-sequenzen für die hemmung der expression des adhäsionsmoleküls icam-1
US6114517A (en) * 1998-12-10 2000-09-05 Isis Pharmaceuticals Inc. Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
US6670321B1 (en) 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
WO2000044409A1 (en) 1999-01-27 2000-08-03 University College London Formulations comprising antisense nucleotides to connexins
DE10019252A1 (de) * 2000-04-18 2001-10-31 Klaus Karl Degitz Polydesoxyribonukleotide zur Hemmung der ICAM-1-Genexpression
DE10141443B4 (de) * 2001-08-23 2007-02-01 Christos C. Prof. Dr. Zouboulis Verwendung von molekularbiologisch hergestellten, nicht-viralen Wirkstoffen zur Behandlung der Akne
KR101350837B1 (ko) 2003-12-03 2014-01-14 코다 테라퓨틱스, 인크. 코넥신에 표적화된 안티센스 화합물 및 그의 사용 방법
KR101840445B1 (ko) 2005-02-03 2018-05-04 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
CN101965193A (zh) 2006-11-15 2011-02-02 科达治疗公司 用于伤口愈合的改进方法和组合物
PL2101791T3 (pl) 2006-12-11 2015-04-30 Coda Therapeutics Inc Preparaty i metody leczenia ran z nieprawidłowym przebiegiem gojenia
JP2011507857A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 線維症性の状態の処置のためのコネキシン４３の阻害剤の使用
CA2958879A1 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
JP2020517714A (ja) 2017-04-28 2020-06-18 オークランド ユニサービシズ リミテッド 処置方法および新規構築物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001286A2 (en) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
WO1994022488A1 (en) * 1993-04-01 1994-10-13 Isis Pharmaceuticals, Inc. ANTISENSE OLIGOS WHICH INTERFERE WITH mRNA CAP ACTIVITY AND INHIBIT TRANSLATION
WO1996015780A1 (en) * 1994-11-23 1996-05-30 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection
US5580969A (en) * 1992-07-24 1996-12-03 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ICAM-I RNA

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284931A (en) * 1987-05-04 1994-02-08 Dana Farber Cancer Institute Intercellular adhesion molecules, and their binding ligands
US5591623A (en) * 1990-08-14 1997-01-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
EP0558697A1 (de) * 1991-06-28 1993-09-08 Massachusetts Institute Of Technology Lokale oligonukleotiden Behandlung

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993001286A2 (en) * 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5580969A (en) * 1992-07-24 1996-12-03 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ICAM-I RNA
WO1994022488A1 (en) * 1993-04-01 1994-10-13 Isis Pharmaceuticals, Inc. ANTISENSE OLIGOS WHICH INTERFERE WITH mRNA CAP ACTIVITY AND INHIBIT TRANSLATION
WO1996015780A1 (en) * 1994-11-23 1996-05-30 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BENNETT C F ET AL: "INHIBITION OF ICAM-1, VCAM-1 AND E-SELECTIN EXPRESSION WITH ANTISENSE OLIGONUCLEOTIDES", JOURNAL OF CELLULAR BIOCHEMISTRY. SUPPLEMENT, 9 January 1993 (1993-01-09), pages 354, XP000647853 *
LEE CH. ET AL.: "Antisense gene suppression against human ICAM-1, ELAM-1, and VCAM-1 in cultured human umbilical vein endothelial cells.", SHOCK 1995 JUL;4(1):1-10, XP000892942 *
See also references of WO9824797A1 *

Also Published As

Publication number Publication date
WO1998024797A1 (en) 1998-06-11
EP0950060A1 (de) 1999-10-20
AU1564897A (en) 1998-06-29
JP2001505432A (ja) 2001-04-24
CA2273203A1 (en) 1998-06-11

Similar Documents

Publication Publication Date Title
EG21382A (en) Treatment of water
PL329875A1 (en) Derivatives of carbolin
PL329195A1 (en) Derivatives of 6-phenylpyridol-2-amine
PL327569A1 (en) Promedications of thrombosin inhibitors
EP1009860A4 (de) Antisense oligonukleotid zur inhibierung von ras
GB9526560D0 (en) Use of 2-Amino-Heterocycles
EP0950060A4 (de) Gegenstrang-hemmung von menschlichen adhäsionsmolekülen
EP0800649A4 (de) Hemmung der gliazellen-proliferation
SG42329A1 (en) Use of phenylcyclohexylcarboxamides
IL113992A0 (en) Use of copolymer-1
HU9702480D0 (en) New polymorphe modification of doxazosin-mesylate
GB9615159D0 (en) Treatment of liquid
ZA969429B (en) Amidinohydrazones of ketones
GB2328397B (en) Manufacture of elongate members
HU9702479D0 (en) New polymorphe modification of doxazosin-mesylate
ZA971958B (en) Treatment of cocoa
IL134210A0 (en) Use of transcription factor brn-3a
AU5126298A (en) Inhibition of crib-biting
AU6920898A (en) Antisense inhibition of human stat-6
AU6578298A (en) Antisense inhibition of angiogenin expression
GB9611315D0 (en) Treatment of painted surfaces
ZA976333B (en) Treatment of obesity
PL313849A1 (en) Beta-aminoesters of o-hydrobenzylamides
GB9724088D0 (en) Treatment of dyskinesia
GB9612603D0 (en) Treatment of biosolids

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990616

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000518

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20020724

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040716